

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00154

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K39/395 A61K31/436 A61P37/08 A61P11/06 //(A61K39/395, 31:436)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EMBASE, EPO-Internal, WPI Data, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 16804 A (DYNAVAX TECHNOLOGIES CORP ;DINA DINO (US)) 30 March 2000 (2000-03-30) page 30, line 27 -page 31, line 20 ---	1-6, 12-17, 23, 26-28, 30,31,36
X	BUSSE WILLIAM ET AL: "Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 108, no. 2, August 2001 (2001-08), pages 184-190, XP008018355 ISSN: 0091-6749 see pg.185 "study design" --- <div style="text-align: center;">-/--</div>	1-6, 12-17, 23, 26-28, 30,31,36
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">18 June 2003</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">25/06/2003</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">COVONE-VAN HEES, M</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00154

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 01 90110 A (FLEISSNER GERHARD ;NOVARTIS ERFIND VERWALT GMBH (AT); NOVARTIS AG) 29 November 2001 (2001-11-29)</p> <p>page 11, paragraph 1</p> <p>---</p>	<p>7-11, 18-22, 24,25, 29,32-35</p>
A	<p>HEUSSER C ET AL: "Therapeutic potential of anti-IgE antibodies" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD. LONDON, GB, vol. 9, no. 6, December 1997 (1997-12), pages 805-813, XP002125679 ISSN: 0952-7915 the whole document</p> <p>---</p>	<p>1-36</p>
A	<p>KUEHR J ET AL: "Omalizumab (XOLAIR(R), RHUMAB-E25) in children with seasonal allergic rhinitis to birch and grass pollen: Superior efficacy of Xolair plus Specific Immunotherapy over Specific Immunotherapy alone during grass pollen season." ALLERGY (COPENHAGEN), vol. 56, no. Supplement 68, 2001, pages 93-94, XP008018356 XXth Congress of the European Academy of Allergology and Clinical Immunology;Berlin, Germany; May 09-13, 2001 ISSN: 0105-4538 abstract</p> <p>-----</p>	<p>1-36</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/00154

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 14-26,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/00154

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0016804	A	30-03-2000	AU 6153799 A	10-04-2000
			CA 2343052 A1	30-03-2000
			EP 1113818 A1	11-07-2001
			WO 0016804 A1	30-03-2000
			US 2003064064 A1	03-04-2003

WO 0190110	A	29-11-2001	AU 7842801 A	03-12-2001
			WO 0190110 A1	29-11-2001
			EP 1289997 A1	12-03-2003
